ABL1 and prostate cancer: PROTACs have already been applied for the degradation of various notable targets, including abelson murine leukemia viral oncogene homolog 1 (ABL)-breakpoint cluster region (BCR) in chronic myeloid leukemia, bromodomain proteins in multiple cancers, and androgen receptor in prostate cancer (details in Table 1)53,71,72.